RIGL
Rigel Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-03
Figures on this page computed 2026-11-08 12:40 UTC
Last close
51.29USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-03-03
1.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-03
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
n/mNet marginnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
- Growth22.1%89 of 100, above its sector
- Returns on capital93.8%99 of 100, above its sector
- Margins93.3%97 of 100, above its sector
- Price1.9x62 of 100, above its sector
- Safety2.4266 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Ten years as a story
lens 9 of 9Every filing we hold, oldest first
10- 2017-03-07Annual report for 201610-K
- 2018-03-06Annual report for 201710-K
- 2019-02-28Annual report for 201810-K
- 2020-02-27Annual report for 201910-K
- 2021-03-02Annual report for 202010-K
- 2022-03-01Annual report for 202110-K
- 2023-03-07Annual report for 202210-K
- 2024-03-05Annual report for 202310-K
- 2025-03-04Annual report for 202410-K
- 2026-03-03Annual report for 202510-K
10 filings over the years we hold, each pinned to the day it landed.
10 filings over the years we hold, each pinned to the day it landed.